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ABSTRACT
Discordant interpretations of the results of clinical trials often drive scientific disputes. 
Our position concerning the protocol and performance of the ISAR-REACT 5 trial have been termed as false and 
groundless in the recently published article. We deeply disagree with this judgement and still maintain all 
our opinions expressed in the previous publications, without any exceptions. As demonstrated in multi-
ple studies, prasugrel has excellent effectiveness and predictability. In our previous publications, it was 
not the drug itself that we put under criticism, but rather the quality of the trial assessing the drug.  As a 
consequence of this critical approach, we stated that taking into account the serious limitations of the 
ISAR-REACT 5 trial, its results should be taken with cautiousness. 
To summarize, we remain open to further creative scientific dispute enriching both readers and authors. 
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Introduction 
Creative scientific dispute presenting results of 
clinical trials from different points of view is a valuable 
tool for enriching the knowledge of the adversaries and 
the readers.
 One of the articles published in the latest issue of 
„Folia Cardiologica”, titled „Modern therapy of acute 
coronary syndromes based on prasugrel — available 
to Polish patients” [1], undermines the arguments 
adduced in our two earlier publications critical of the 
methodology of the ISAR-REACT 5 trial [2, 3].  As au-
thors of the former two publications, we feel obliged to 
refer to these objections.
We are deeply convinced that criticism can be of 
a stimulative value only when not left unresponded. 
Critical analysis and dispute
The majority of our remarks concerning the protocol 
of the ISAR-REACT 5 trial [4] and its performance [5] 
were termed by our opponent as false and ground-
less. We deeply disagree with this judgement and still 
maintain all our opinions expressed in the previous 
publications [2, 3], without any exceptions. 
The long-anticipated results of the ISAR-REACT 
5 trial comparing ticagrelor with prasugrel turned out to 
be a surprise, pointing to superiority of prasugrel over 
ticagrelor and contradicting the trial’s initial assumptions 
[4, 5]. In our opinion this contradiction whatsoever does 
not enhance the validity of the results of the trial. 
Our dispute adversary, truthfully notices our criticism 
of the open character of the trial, underestimation of 
non-compliance to recommended therapy and the 
form of follow-up based on telephone calls. Further, she 
states that these features in fact underlie the strength of 
the trial, rendering it closer to everyday clinical reality 
rather than concentrating on a highly selected popula-
tion of a clinical trial [1]. We disagree with this opinion 
– none of the mentioned factors (open character of the 
trial, compliance underestimation, indirect contact with 
the patient) are relevant regarding the trial’s inclusion 
and exclusion criteria and as such, they remain irrele-
vant with respect to patient selection. In our opinion, the 
situation is exactly opposite. The assumption of nearly 
absolute compliance (according to the authors of the 
ISAR-REACT 5 trial amounting 99.1% and 99.6% in the 
prasugrel and ticagrelor arm, respectively) seems quite 
risky and in fact it moves the results away from reality, 
rather than renders them closer to it [2, 3].
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Our opponent’s [1] astonishment derived from 
our remarks concerning the ITT-type of analysis (in-
tention-to-treat – population receiving the originally 
assigned treatment) and inclusion of patients who 
eventually did not receive the medication as originally 
allocated, is quite incomprehensible as we clearly stated 
an opposite fact, namely, that such method is common-
ly accepted in this type of clinical trials. However, in this 
specific case, taking into account the exceptionally high 
rate of study drug discontinuation (ticagrelor arm: 653 of 
2012 patients (32%), prasugrel arm: 609 of 2006 pa-
tients (30.4%)), a significant bias might have occurred 
[5]. Therefore, it is not the methodology that we subject 
to criticism, but only the possible consequences of in-
cluding into the analysis a surprisingly high number of 
patients who in fact were not treated with the originally 
assigned drug [2, 3]. Of note, among the 4018 patients 
randomized for the trial, the study drugs were discon-
tinued in 820 (20.4%) of them within first few days after 
randomization, even before discharge from hospital [5].
According to our opponent, it is quite unlikely 
that the difference in the rate of the primary endpoint 
(death, myocardial infarction or stroke) within a year 
following randomization between the ticagrelor (9.8%) 
and prasugrel (6.8%) arm is insignificant [1]. In order 
to clarify, we would like to clearly state that in our both 
publications a detailed statistical analysis of the primary 
endpoint in the ISAR-REACT 5 trial was presented [2, 
3]. However, we also included information, which due 
to space constraints was published in the supplemental 
contents outside the main text, telling that the on-treat-
ment analysis did not show significant differences be-
tween the study arms regarding the primary endpoint 
occurrence between discharge from hospital and either 
therapy discontinuation or follow-up completion [5]. 
We also highlighted that taking into account the fact 
that 1262 patients of those included in the analysis 
had had the study drug discontinued, while 37 patients 
were lost to follow-up, the absolute difference between 
both study groups in the primary endpoint occurrence 
amounted barely 47 cases and can hardly be consid-
ered significant [2, 3].
Our adversary also disagrees with our objections 
concerning the ISAR-STAR 5 trial, resulting from the 
comparison of its results with the outcomes reported 
for the TRITON-TIMI38 trial. She also finds our position 
stating that the differences in the primary endpoint rates 
between these both trials (6.9% for ISAR-REACT 5 ver-
sus 9.9% for TRITON-TIMI 38) seem unexpected and 
hard to explain, to be surprising [1]. In response to these 
remarks – stating that such differences in outcomes be-
tween the both trials exist is simply acknowledging a fact 
rather than raising an objection against the ISAR-REACT 
5 trial [5, 6]. Regarding the other remark, we admit that 
we were and still are startled with this difference, and we 
seem to be not the only ones, as the outcomes of the 
ISAR-STAR 5 trial were an unexpected finding even for 
the authors of the trial [5]. We admit, we cannot explain 
the magnitude of the difference and we remain open for 
any explanatory suggestions for this fact.  Interestingly, 
the major difference in the occurrence of the primary 
endpoint between the prasugrel arms of the ISAR-RE-
ACT 5 and TRITON-TIMI38 trials was not accompanied 
by analogous difference between the ticagrelor arms 
of these trials [5]. 
The Orville Wright quote: “If we all worked on the 
assumption that what is accepted as true is really true, 
there would be little hope of advance.” used by our 
opponent as a comment, although otherwise arousing 
appreciation, in our opinion, in this specific setting is 
misguided and wrongful.  We are deeply convinced 
that none of our two criticized papers [2, 3], neither our 
previous publications regarding antiaggregation thera-
py [7–74], legitimate assumptions that our intention is 
inhibition of progress through creation of opinion stag-
nation, instead of quest for the truth aimed at advance.
The closing critical remark addressed at our publica-
tions argues against our objections regarding the lack 
of identification of causes for patient exclusion from the 
safety analysis, pointing that such causes were reported 
in the original publication of the ISAR-REACT 5 trial [1]. 
Unfortunately, we cannot support this point of view, as 
the original report reveals that in 172 and 184 patients 
respectively randomized to ticagrelor and prasugrel, 
the initial diagnosis of acute coronary syndrome was 
not confirmed. According to the trial protocol, the 
consequence of this fact in case of prasugrel should 
be desisting from drug administration, in conjunction 
with exclusion of these patients from the safety analysis 
(modified intention to treat). The numbers reported in 
the original publication were 23 and 233 respectively 
and they do not correspond to the numbers of patients 
with unconfirmed diagnosis of acute coronary syn-
drome, while no explanation for the real numbers of 
exclusions in both groups were presented [5].
Following the critical review of our position, our 
opponent highlights the excellent results of acute cor-
onary syndrome treatment based on prasugrel, in an 
attempt to convince the readers about the advantages 
of this P2Y12 receptor inhibitor [1]. In this aspect, we 
fully support her point of view, however in the global 
context of the paper, the initial reference to ticagrelor 
in the summary paragraph may surprise. The author 
indicates that ticagrelor is likely to produce intermittent 
dyspnea, occasionally leading to drug discontinuation 
[1], however she omits the crucial fact that ticagrelor 
is the only antiplatelet agent with proven reduction in 
cardiovascular mortality and all-cause mortality [75].   
Juxtaposition of the final portion of the paper with 
its earlier part, critical of our publications, brings to 
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mind an attempt of defending prasugrel.  In this as-
pect, this action resembles convincing ones who are 
already convinced as prasugrel needs no defense.  The 
effectiveness and predictability of prasugrel has been 
demonstrated in numerous publications, also those 
coming from our research team [11, 17, 25, 26, 35, 38, 
39, 46, 60, 62, 69], and undeniably prasugrel holds 
a strong position in multiple guidelines.  
We would like to clearly stress that the critical re-
marks presented in our publications strictly apply to the 
quality of the drug-assessing study, not the drug itself. 
That is why we concluded that concerning the serious 
shortcomings of the ISAR-REACT 5 trial, its results 
should be taken with cautiousness [2, 3]. 
Concluding, we remain open to further creative 
scientific dispute enriching both readers and authors. 
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